# BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

> **NCT00207051** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 62 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Brivanib + Cetuximab

## Key facts

- **NCT ID:** NCT00207051
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2011-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00207051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00207051, "BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00207051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*